Skip to main content
. Author manuscript; available in PMC: 2021 Nov 15.
Published in final edited form as: Clin Cancer Res. 2021 Mar 8;27(10):2920–2927. doi: 10.1158/1078-0432.CCR-20-4650

Figure 3: Immunophenotype of exon 20 insertion cases.

Figure 3:

A. Median tumor mutational burden (TMB) from available cases is significantly lower in EGFR exon 20 insertion (ex20ins) cases compared to both EGFR del 19/L858R tumors and NSCLC tumors without EGFR ex20ins B. Tumor PD-L1 expression was quantified as low (<1%), intermediate (1–49%) and high (≥50%) for available cases and tabulated across ex20ins, EGFR del19/L858R cases, and NSCLC without EGFR ex20ins tumors.